UiPath (NYSE:PATH) Shares Down 0.4%

Shares of UiPath Inc. (NYSE:PATH) were down 0.4% during mid-day trading on Wednesday . The company traded as low as $19.15 and last traded at $19.41. Approximately 7,327,104 shares were traded during mid-day trading, an increase of 21% from the average daily volume of 6,060,729 shares. The stock had previously closed at $19.48.

Analyst Ratings Changes

A number of equities analysts have issued reports on PATH shares. JPMorgan Chase & Co. upgraded shares of UiPath from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $22.00 to $28.00 in a research report on Thursday, March 14th. Scotiabank boosted their price objective on shares of UiPath from $29.00 to $30.00 and gave the company a “sector perform” rating in a research report on Thursday, March 14th. TD Cowen boosted their price objective on shares of UiPath from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, March 14th. Morgan Stanley boosted their price objective on shares of UiPath from $17.00 to $25.00 and gave the company an “equal weight” rating in a research report on Thursday, March 14th. Finally, KeyCorp started coverage on shares of UiPath in a research report on Monday, April 8th. They issued an “overweight” rating and a $27.00 price objective on the stock. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $27.41.

UiPath Price Performance

The firm has a market capitalization of $11.04 billion, a P/E ratio of -114.17 and a beta of 0.96. The company’s 50-day simple moving average is $23.16 and its two-hundred day simple moving average is $21.47.

UiPath (NYSE:PATH) last released its quarterly earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.10. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. The business had revenue of $405.25 million for the quarter, compared to the consensus estimate of $383.32 million. Analysts predict that UiPath Inc. will post -0.04 earnings per share for the current year.

Insider Activity at UiPath

In other UiPath news, CFO Ashim Gupta sold 16,000 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $22.84, for a total transaction of $365,440.00. Following the completion of the transaction, the chief financial officer now owns 87,505 shares in the company, valued at $1,998,614.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders sold 72,000 shares of company stock valued at $1,591,360. Corporate insiders own 31.03% of the company’s stock.

Hedge Funds Weigh In On UiPath

Several institutional investors have recently bought and sold shares of the business. Intech Investment Management LLC lifted its holdings in shares of UiPath by 3.1% in the 4th quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock worth $356,000 after acquiring an additional 426 shares during the last quarter. 180 Wealth Advisors LLC lifted its holdings in shares of UiPath by 0.3% in the 4th quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock worth $4,497,000 after acquiring an additional 492 shares during the last quarter. Bleakley Financial Group LLC lifted its holdings in UiPath by 4.9% during the 4th quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after buying an additional 598 shares in the last quarter. Simplicity Solutions LLC lifted its holdings in UiPath by 4.9% during the 4th quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after buying an additional 598 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in UiPath by 40.2% during the 1st quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company’s stock valued at $50,000 after buying an additional 632 shares in the last quarter. Institutional investors own 62.50% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.